Antimetabolites Flashcards

1
Q

Describe antimetabolites

A

Drugs that interfere w formation of key biomolecules within the cell
Several classes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are three classes of antimetabolites

A

Folate antagonists
Pyrimidine antagonists
Purine antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe folic acid

A

Essential water-soluble B vitamin
Acquired through diet, body can’t synthesise it
Require 400mg per day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe folates as coenzymes

A

Help in the synthesis of nucleotide precursors
One carbon donors
Only active in fully reduced form

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe the de novo synthesis reaction of dUMP to dTMP via folate

A

Catalysed by thymidylate synthase
Folate in tetra hydrofolate form donates carbon group -> dihydrofolate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the fully reduced form of folate called

A

Tetrahydrofolate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the role of dihydrofolate reductase

A

Reduced dihydrofolate -> tetrahydrofolate to make the folate fully reduced so it can be used again
Uses NADPH as co factor to reduce fol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe folates involvement in purine synthesis

A

Co factor in de novo purine synthesis to form IMP -> GMP and AMP

Alongside GAR and AICAR transformylases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe intracellular polyglutamation

A

Via folypolyglutamate synthetase
Adds glutamate residues to folate to make it larger and anionic = intracellular accumulation and retention

Enhances cofactor affinity in purine pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe antifolates

A

Folate analogues
Tight binding inhibitor not substrate for dihydrofolate reductase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is methotrexate

A

Antifolate
Widely used in many tumour types
Used in non-malignant conditions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the mechanism of action for MTX

A

Glutamated by folypolyglutamate
Inhibits dihydrofolate reductase
= inhibits thymidylate synthesis
= build up of dUMP and dihydrofolate

= can’t generate dDTPs
= inhibits GART and AICART

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

When is MTX a stronger inhibitor of thymidylate synthetase

A

When it has been glutamated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Why is there better retention of MTX In tumour cells

A

High polyglutamation formation in malignant cells
= 80% MTX polyglutamated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the biochemical consequences of MTX

A

Decreased dTTP and increased dUTP
= inappropriate incorporation of U into DNA
Inhibition of chain elongation
-> excision of U = strand breaks -> death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How does MTX enter the cells

A

Via passive diffusion at high concs
= temp sensitive and energy dependent

Via reduced folate carrier

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How does folic acid enter the cell

A

Via the folate receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

How does serum folate enter the cell

A

Via folate receptors or the reduced folate carrier

19
Q

How can malignant cells affect the folate carrier to form resistance to MTX

A

Decrease expression = reduced amount of MTX into cell

20
Q

How can malignant cells reduced the amount of glutamate MTX to form resistance

A

Enhanced levels of gammaGH or decreased levels of FPGS enzyme activity

MTX not well retained and has less affinity for enzymes

21
Q

How does a malignant cells form resistance against MTX via DHFR

A

Specific mutation = decreased DHFR binding to MTX but still allow dihydrofolate bind

22
Q

How can malignant cells affect gene expression to form resistance to MTX

A

Amplification of DHFR at gene level
= more protein
= not enough MTX to sufficiently inhibit

23
Q

Describe the pharmacology of MTX

A

Oral/IV or intrathecal administration
1st phase half life = 3 hours
Final phase half life = 8-10 hours

24
Q

How is MTX excreted

25
What toxicities are expected with MTX
Myelosuppression, mucositis and nephrotoxicity
26
What does require LV rescue
Intermediate and high 100mg/m2 +
27
What is the role of LV
Prevents/ rescues cells from toxic effects of MTX Can prevent toxicity to bone marrow and GI tract
28
What is the mechanism of action for LV
Competitor for transport/ polyglutamation and targeted enzymes
29
Is MTX inhibition reversible
Yes Can be out competed with FH2 or reduced folates
30
What else can be used to rescue cells instead of LV
Thymidine
31
Name 2 new antifolates
Pralatrexate Pemetexed
32
Describe pralatrexate
10x greater affinity for RFC than MTX Higher polyglutamation Inhibits tumour cell growth at lower conc
33
Describe Pemetrexed
Readily transported into cells via RFC Multitargeted antifolate, mainly TS but also DHFR and GART
34
Describe purine and pyrimidine anti-metabolites
Analogues for bases and nucleosides = Inhibits DNA synthesis
35
Name pyrimidine anti-metabolites
5-flurouracil Cytosine arabinoside
36
Name purine anti-metabolites
Mercaptopurine Thiogunaine
37
Describe 5-fluorouracil
Analogue of uracil with F atom on C5 Causes replication errors Requires intracellular metabolism to cytotoxic forms
38
What can be used to inhibit thymidylate synthase
FdUMP In the presence of folate cofactor Competes with dUMP for catalytic site
39
What is another mechanism that 5-FU uses
Incorporates into RNA Inhibits RNA processing Incorporated into DNA - strand breaks
40
Describe the catabolism of 5-FU
Initial reduction by DPD Final breakdown product is FBAL
41
What can low DPD activity cause
Increased exposure to active metabolites = results in severe or fatal toxicity
42
What is advised prior to 5FU treatment
DPD status e.g enzyme activity and SNP presence
43
Describe the pharmacology of 5FU
Poor oral bioavailability (25-45%) -> DPD inhibitor = 100% Saturable first pass metabolism High clearance Half life 10-20mins -> 5hrs